Aurobindo Pharma provided update on USFDA Inspection

23rd May 2011

In continuation to our press release dated 23rd February 2011 for US Food & Drug Administration (USFDA) action on Unit VI, the company has now received the Warning Letter from USFDA detailing their observations.

In addition, based on a field alert report for packaging and labeling compliance for unit III, the USFDA has also asked for submission of a detailed action plan for improvement in this letter.

This is required to be submitted within 15 working days and USFDA has also given an opportunity for regulatory meeting at their office.

The company is requesting USFDA for the meeting date as well as in the process of submitting a detailed action plan.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com